Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies


BBI-825 is a novel, oral, selective ribonucleotide...

Related Keywords

San Diego ,California ,United States ,Rona Yaeger ,Klaus Wagner ,Zachary Hornby ,Linkedin ,Exchange Commission ,Twitter ,Boundless Bio ,Chief Medical Officer ,Gastrointestinal Oncologist ,Early Drug Development Specialist ,Memorial Sloan Kettering Cancer ,Chief Executive Officer ,Treating Acquired Resistance ,Private Securities Litigation Reform Act ,Markets ,